Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure

TY - JOUR

T1 - Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure

AU - Farquharson, C A J

AU - Struthers, A D

PY - 2002

Y1 - 2002

N2 - To test whether simply increasing plasma potassium with amiloride would exert any of the same beneficial effects on "surrogate outcome measures" that are seen with spironolactone. The latter has been shown to improve mortality in chronic heart failure, possibly as a result of improvements in endothelial dysfunction, vascular angiotensin converting enzyme (ACE), autonomic function, myocardial fibrosis, ventricular arrhythmias, and QT interval indices.

AB - To test whether simply increasing plasma potassium with amiloride would exert any of the same beneficial effects on "surrogate outcome measures" that are seen with spironolactone. The latter has been shown to improve mortality in chronic heart failure, possibly as a result of improvements in endothelial dysfunction, vascular angiotensin converting enzyme (ACE), autonomic function, myocardial fibrosis, ventricular arrhythmias, and QT interval indices.

U2 - 10.1136/heart.88.5.475

DO - 10.1136/heart.88.5.475

M3 - Article

C2 - 12381637

SN - 1468-201X

VL - 88

SP - 475

EP - 480

JO - Heart (British Cardiac Society)

JF - Heart (British Cardiac Society)

IS - 5

ER -